Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06738368 | Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia | suspended | Phase 2 | 30 | University of WashingtonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03494569 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome | suspended | Phase 1 | 36 | City of Hope Medical Center |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT06197672 | Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | suspended | Phase 1 | 30 | Huda SalmanOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06421155 | Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia | suspended | N/A | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07313592 | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients | suspended | — | 60 | Washington University School of MedicineOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | suspended | Phase 2 | 20 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06514261 | Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML | suspended | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06802523 | Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia | suspended | Phase 1 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03728335 | Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation | suspended | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06492707 | DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial | suspended | Phase 1 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | suspended | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03969446 | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | suspended | Phase 1 | 54 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | suspended | Phase 1 | 12 | David WaldOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06447987 | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia | suspended | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | suspended | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06171152 | Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues | suspended | Early Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04278768 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | suspended | Phase 1 / Phase 2 | 366 | Curis, Inc.INDUSTRY | 8 | Mar 19, 2026 | clinicaltrials |
| NCT06626633 | 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML | suspended | Phase 1 | 6 | University of Maryland, BaltimoreOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03467386 | Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia | suspended | Phase 1 | 56 | City of Hope Medical CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06709131 | A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia(CT0991) | suspended | Phase 1 | 24 | He HuangOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06454409 | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia | suspended | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06639958 | A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home | suspended | N/A | 64 | Children's Oncology GroupNETWORK | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04996030 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | suspended | Phase 1 | 16 | Syros PharmaceuticalsINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | suspended | Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04485052 | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia | suspended | Phase 1 / Phase 2 | 222 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03229876 | Safety and Efficacy Evaluation of CD19-UCART | suspended | N/A | 20 | Bioray LaboratoriesINDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia | suspended | Phase 1 | 20 | National University Health System, SingaporeOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT02462265 | Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients | suspended | Phase 2 | 15 | Oshadi Drug AdministrationINDUSTRY | 0 | Apr 18, 2018 | clinicaltrials |
| NCT01709396 | ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS(ED-TBI) | suspended | Phase 2 | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01010373 | Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients | suspended | Phase 2 | 12 | BioMAS LtdINDUSTRY | 1 | Feb 10, 2015 | clinicaltrials |
| NCT00991744 | Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) | suspended | Phase 3 | 100 | Nordic Society for Pediatric Hematology and OncologyOTHER | 5 | Oct 10, 2012 | clinicaltrials |
| NCT00329498 | L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes | suspended | Phase 2 | 25 | Samsung Medical CenterOTHER | 1 | Oct 26, 2006 | clinicaltrials |
Data updated 8 hours agoSource updated Sep 29, 2026source: clinicaltrials